Construction, expression and functional characterization of the β-lactamase with αv integrin ligands

Protein and Peptide Letters

Volumn 17, Issue 12, 2010, Pages 1562-1565

  Wang, Hao ^a   Shi, Pei Ji ^a   Wu, Ming Fen ^a   Li, Ning ^a   Zhou, Xiao Liang ^a   Fan, Fei Yue ^a  

^a INSTITUTE OF RADIATION MEDICINE   (China)

Author keywords

ADEPT; Recombinant protein; RGD4C; Lactamase

Indexed keywords

MAMMALIA;

EID: 78650661678     PISSN: 09298665     EISSN: None     Source Type: Journal    
DOI: 10.2174/0929866511009011562     Document Type: Article

References (13)

1. Bagshawe, K.D.; Sharma, S.K.; Begent, R.H. Antibody-directed enzyme prodrug therapy (ADEPT) for cancer. Expert Opin. Biol. Ther., 2004, 4(11), 1777-1789.
2. Senter, P.D.; Springer, C.J. Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates. Adv. Drug De-liv. Rev., 2001, 53(3), 247-264.
3. Springer, C.J.; Niculescu-Duvaz, I. Antibody-directed enzyme prodrug therapy (ADEPT): A review. Adv. Drug Deliv. Rev., 1997, 26(2-3), 151-172.
4. Wang, H.; Chen, K.; Cai, W.; Li, Z.; He, L.; Kashefi, A.; Chen, X. Integrin-targeted imaging and therapy with RGD4C-TNF fusion protein. Mol. Cancer Ther., 2008, 7(5), 1044-1053.
5. Curnis, F.; Gasparri, A.; Sacchi, A.; Longhi, R.; Corti, A. Coupling tumor necrosis factor-α, integrin ligands improves its antineoplastic activity. Cancer Res., 2004, 64(2), 565-571.
6. Curnis, F.; Sacchi, A.; Borgna, L.; Magni, F.; Gasparri, A.; Corti, A. Enhancement of tumor necrosis factor α antitumor immuno-therapeuties by targeted delivery to aminopeptidase N (CD13). Nat. Biotechnol., 2000, 18(11) ,1185-1190.
7. Pasqualini, R.; Koivunen, E.; Kain, R.; Lahdenranta, J.; Sakamoto, M.; Stryhn, A.; Ashmun, R.A.; Shapiro, L.H.; Arap, W.; Ruoslahti, E. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res., 2000, 60(3), 722-727.
8. Pasqualini, R.; Koivunen, E.; Ruoslahti, E. Alpha v integrins as receptors for tumor targeting by circulating ligands. Nat. Biotech-nol., 1997, 15(6), 542-546.
9. Lord, R.; Parsons, M.; Kirby, I.; Beavil, A.; Hunt, J.; Sutton, B.; Santis, G. Analysis of the interaction between RGD-expressing adenovirus type 5 fiber knob domains and alphavbeta3 integrin reveals distinct binding profiles and intracellular trafficking. J. Gen. Virol., 2006, 87(Pt 9), 2497-2505.
10. Song, N.L.; He, X.; Zhao, Q.R.; Yan, T.D.; Wen, L. Cloning and expression of the tumstatin active peptides-T7 and its derivant-T7-NGR. Clin. Exp. Med., 2009, 9(2), 165-171.
11. Kerr, D.E.; Li, Z.; Siemers, N.O.; Senter, P.D.; Vrudhula, V.M. Development and activities of a new melphalan prodrug designed for tumor-selective activation. Bioconjugate Chem., 1998, 9(2), 255-259.
12. Alderson, R.F.; Toki, B. E.; Roberge, M.; Geng, W.; Basler, J.; Chin, R.; Liu, A.; Ueda, R.; Hodges, D.; Escandon, E.; Chen, T.; Kanavarioti, T.; Babe, L.; Senter, P.D.; Fox, J.A.; Schellenberger, V. Characterization of a CC49-based single-chain fragment-β-lactamase fusion protein for antibody-directed enzyme prodrug therapy (ADEPT). Bioconjugate Chem., 2006, 17(2), 410-418.
13. Harding, F.A.; Liu, A.D.; Stickler, M.; Razo, O.J.; Chin, R.; Faravashi, N.; Viola, W.; Graycar, T.; Yeung, V.P.; Aehle, W.; Meijer, D.; Wong, S.; Rashid, M.H.; Valdes, A.M.; Schellenberger, V. A beta-lactamase with reduced immunogenicity for the targeted delivery of chemotherapeutics using antibody-directed enzyme prodrug therapy. Mol. Cancer Ther., 2005, 4(11), 1791-1800.